Loading data for LZAGF — first visit, this takes a few seconds.
Lonza Group AG
658.21 +7.00 (1.07%)
- Market Cap
- $45.97B
- Volume
- 19
- Dividend yield
- 0.98%
- Next earnings date
- Jan 28, 2027
Lonza Group AG (LZAGF) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | — | n/a | n/a |
| EPS | — | n/a | n/a |
Metrics
- Bid
- 629.5
- Market Cap
- 46B
- Revenue (ttm)
- 6.87B
- Net Income (ttm)
- 1.08B
- 0.84
- 19.15
- 34.37
- n/a
- P/B (ttm)
- 4.58
- P/S (ttm)
- 6.69
- Earnings Date
- Jan 28, 2027
- Ask
- 681.5
- Volume
- 19
- Avg. Volume (20D)
- 288
- Open
- 658.21
- Previous Close
- 651.21
- Day's Range
- 658.21 - 658.21
- 52-Week Range
- 565.14 - 755.96
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- $6.38 (0.98%)
- Ex-Dividend Date
- May 12, 2026
About Lonza Group AG
View profile →Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Industry Diagnostics & Research
Sector Healthcare
IPO Date Feb 13, 2009
Employees 20,141
Stock Exchange OTC Markets OTCPK
Ticker Symbol LZAGF
Website https://www.lonza.com